Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

This study has been completed.
Information provided by:
Abbott Identifier:
First received: March 26, 2008
Last updated: NA
Last verified: March 2008
History: No changes posted
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: March 2004 (Final data collection date for primary outcome measure)